Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergen Injection Immunotherapy for Grass Pollen Hayfever (Up-dosing Study)
NCT00135629Phase 3Completed
- Sponsor
- Imperial College London
- Start
- Oct 2002
- Primary completion
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alutard-sq in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Imperial College London. Primary endpoints: Symptom and medication score at 12 months and Adverse events (conjunctival symptoms) at 12 months. Started Oct 2002; status: completed.
02
Drugs
alutard-sq
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00135629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135629.